Skip to main content
News

Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR T-Cell Therapy

Results from a Multicenter Observational Study

Jordan Kadish

According to findings from a multicenter observational study published in the American Journal of Hematology, CAR-HEMATOTOX (HT) scores demonstrated value in predicting treatment outcomes and toxicity risks among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). High baseline HT scores (≥2) at the time of lymphodepletion before CD19-directed chimeric antigen receptor (CAR) T-cell therapy with brexucabtagene autoleucel were associated with adverse efficacy and safety outcomes compared to low HT scores (0 to 1). 

CD19-directed CAR T-cell therapy with brexucabtagene autoleucel has increased durable responses among patients with MCL. However, side effects and toxicities such as cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and hematological toxicity remain clinically relevant side effects which contribute to non-relapse mortality (NRM). 

Kai Rejeski, MD, LMU Munich, Munich, Germany, and coauthors stated, “Fatal infections now represent the driving determinant of NRM,” adding that, “no early risk-stratification system for hematological toxicity, infections, and survival outcomes has been validated for R/R MCL patients.”

In this study, investigators aimed to assess the relationship between baseline HT scores and treatment-related toxicity events, NRM, progression-free survival, and overall survival among patients with R/R MCL. 

At the time of lymphodepletion, this study classified 56 patients as HT-low, with a score of 0 to 1, and 47 patients as HT-high, with a score ≥2. All 103 patients received brexucabtagene autoleucel between December 15 and July 2022. The study authors examined the efficacy and safety implications of these scores, particularly with hematotoxicity and infections, through multivariate analysis. Patients in the HT-high cohort experienced significantly prolonged neutropenia, with a median of 14 days versus 6 days in the HT-low cohort. The HT-high cohort also had a notably higher incidence of severe infections (30%) compared to the HT-low cohort (5%). The overall NRM at 1 year was 10.4%, with infections being the primary cause, and rates differencing significantly between high baseline HT score (17%) versus low baseline HT score (4.6%). 

The HT-high cohort experienced inferior efficacy outcomes compared to the HT-low group in terms of 90-day complete response rate (68% versus 93%), median progression-free survival (9 months versus not reached), and median overall survival (26 months versus not reached). Multivariable analyses revealed that high HT scores remained independency associated with severe hematotoxicity, increased susceptibility to infections, and poor survival outcomes. 

Dr Rejeski et al concluded, “the HT score enables early risk-stratification of MCL patients into a high vs. low risk for prolonged neutropenia, severe infections, and poor survival outcomes.” 

“The score will enable individualized toxicity management strategies that spare over-treatment in low-risk candidates, while mitigating the sequelae of toxicity in high-risk patients. Finally, the score could aid with patient selection and help to identify ultra-high-risk candidates in need of further treatment optimization,” they added. 


Source: 

Rejeski K, Wang Y, Albanyan O, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023; 1-12. doi:10.1002/ajh.27056